Hope for patients with aggressive breast cancers

New approach led by St John's Fellow is improving survival rates for women with breast cancer

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, say Cambridge researchers led by a St John’s academic.

In a trial where cancers were treated with chemotherapy followed by a targeted cancer drug before surgery, 100 per cent of patients survived the critical three-year period post-surgery.

Professor Jean Abraham, left, with Jackie Van Bochoven

Trial leader Professor Jean Abraham, a consultant at Addenbrooke’s Hospital, Professor of Precision Breast Cancer Medicine and a Fellow of St John’s, said: “It is rare to have a 100 per cent survival rate in a study like this and for these aggressive types of cancer.

“We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers.”

Around one in 400 people carry mutations in either the BRCA 1or BRCA 2 genes.

Jackie Van Bochoven, 59, from Cambridgeshire, has a family history of breast cancer and carries a faulty copy of the BRCA1 gene, which significantly raises her risk of the disease during her lifetime and those of her three daughters.

She was diagnosed with an aggressive breast tumour in 2019and took part in the trial, called Partner. Jackie said: “When I had the diagnosis, I was completely shocked and numb, I thought about my children, and my mum and sister who were diagnosed with breast cancer. I was pretty worried.

“Six years on, I’m well and cancer free. I’m back at work, enjoying life and spending time with my family. When you’ve had cancer, I think you look at life differently and every day is a bonus.”

The research has been published in Nature Communications and Professor Abraham and team are now planning a larger, multinational trial with 600 patients to validate its results.

The findings have the potential to be applied to other cancers caused by faulty copies of BRCA genes, such as some ovarian, prostate and pancreatic cancers.

Michelle Mitchell, Chief Executive of Cancer Research UK, said: “While this research is still in its infancy, it is an exciting discovery that adding olaparib at a carefully-timed stage of treatment can potentially give patients with this specific type of breast cancer more time with their loved ones.

“Research like this can help find safer and kinder ways to treat certain types of cancer. Further studies in more patients are needed to confirm whether this new technique is safe and effective enough to be used by the NHS.”

The Partner trial was sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, funded by Cancer Research UK and AstraZeneca, and supported by the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre and Addenbrooke’s Charitable Trust (ACT).

Reference

Abraham, JE et al. Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.

Nat Comms; 13 May 2025;DOI: 10.1038/s41467-025-59151-0

Research
News

Related articles

Photo of a graduation procession from St John's College, Cambridge
Research Fellowship competition 2026 launches for early-career academics

The St John’s College Research Fellowships provide rising stars of academia with a rare opportunity to pursue post-doctoral research in an interdisciplinary community

News
Research
A head and shoulders photograph of Glen Whitehead
New Development Director appointed at St John’s

“We look forward to building on our strong tradition of philanthropic generosity”

News
A photo of Vona Groarke in front of the Bridge of Sighs, St John's College, Cambridge
Writer-in-residence named as Ireland Professor of Poetry

Distinguished role bestowed upon poet described as ‘one of the best writers in Ireland today’

News
A photograph of Jack Welland, a PhD researcher at St John's College, Cambridge, sitting at his computer desk, turned towards the camera and smiling
Student discovers how mutations cause childhood neurological diseases

Mapping of a key brain enzyme reveals links to childhood disability and cancer – and could unlock new drug therapies

News
Research